Compare FBRT & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FBRT | TBPH |
|---|---|---|
| Founded | 2012 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 882.8M | 1.0B |
| IPO Year | N/A | 2013 |
| Metric | FBRT | TBPH |
|---|---|---|
| Price | $9.28 | $18.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $14.00 | ★ $27.80 |
| AVG Volume (30 Days) | ★ 1.2M | 386.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 8.86% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.88 |
| Revenue | N/A | ★ $15,386,000.00 |
| Revenue This Year | $25.99 | $70.90 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $13.56 | $21.66 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.42 | $7.90 |
| 52 Week High | $13.58 | $21.03 |
| Indicator | FBRT | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 44.42 | 38.56 |
| Support Level | $8.42 | $13.58 |
| Resistance Level | $10.98 | $19.04 |
| Average True Range (ATR) | 0.26 | 0.95 |
| MACD | -0.03 | -0.14 |
| Stochastic Oscillator | 44.96 | 9.89 |
Franklin BSP Realty Trust Inc is a private real estate investment trust that originates, acquires, and manages a diversified portfolio of commercial real estate debt, and first mortgage loans. secured by properties located in the United States. Its segments include the real estate debt business; the real estate securities business; the real estate owned business; and the commercial real estate conduit business.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).